FibroBiologics director Kathleen Hallisey Rubins files initial beneficial ownership statement
FBLG•Director reports stock option grant
- FibroBiologics director Kathleen Hallisey Rubins reported a stock option for 562 common shares at $65.6, expiring Sept. 26, 2032.
